vs

Side-by-side financial comparison of Citi Trends Inc (CTRN) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Citi Trends Inc is the larger business by last-quarter revenue ($197.1M vs $151.7M, roughly 1.3× Tarsus Pharmaceuticals, Inc.). Citi Trends Inc runs the higher net margin — -3.5% vs -5.5%, a 2.0% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 10.1%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $767.0K). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -4.3%).

Citi Trends, Inc. is an American retail clothing chain selling discounted products targeted primarily at African-American customers.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

CTRN vs TARS — Head-to-Head

Bigger by revenue
CTRN
CTRN
1.3× larger
CTRN
$197.1M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+118.3% gap
TARS
128.4%
10.1%
CTRN
Higher net margin
CTRN
CTRN
2.0% more per $
CTRN
-3.5%
-5.5%
TARS
More free cash flow
TARS
TARS
$12.2M more FCF
TARS
$13.0M
$767.0K
CTRN
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-4.3%
CTRN

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
CTRN
CTRN
TARS
TARS
Revenue
$197.1M
$151.7M
Net Profit
$-6.9M
$-8.4M
Gross Margin
Operating Margin
-3.7%
-5.3%
Net Margin
-3.5%
-5.5%
Revenue YoY
10.1%
128.4%
Net Profit YoY
3.6%
63.8%
EPS (diluted)
$-0.86
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTRN
CTRN
TARS
TARS
Q4 25
$197.1M
$151.7M
Q3 25
$190.8M
$118.7M
Q2 25
$201.7M
$102.7M
Q1 25
$211.2M
$78.3M
Q4 24
$179.1M
$66.4M
Q3 24
$176.6M
$48.1M
Q2 24
$186.3M
$40.8M
Q1 24
$215.2M
$27.6M
Net Profit
CTRN
CTRN
TARS
TARS
Q4 25
$-6.9M
$-8.4M
Q3 25
$3.8M
$-12.6M
Q2 25
$871.0K
$-20.3M
Q1 25
$-14.2M
$-25.1M
Q4 24
$-7.2M
$-23.1M
Q3 24
$-18.4M
$-23.4M
Q2 24
$-3.4M
$-33.3M
Q1 24
$3.6M
$-35.7M
Operating Margin
CTRN
CTRN
TARS
TARS
Q4 25
-3.7%
-5.3%
Q3 25
1.8%
-12.2%
Q2 25
0.2%
-21.6%
Q1 25
0.6%
-33.5%
Q4 24
-4.9%
-36.8%
Q3 24
-14.1%
-52.3%
Q2 24
-3.7%
-81.6%
Q1 24
1.8%
-136.5%
Net Margin
CTRN
CTRN
TARS
TARS
Q4 25
-3.5%
-5.5%
Q3 25
2.0%
-10.6%
Q2 25
0.4%
-19.8%
Q1 25
-6.7%
-32.1%
Q4 24
-4.0%
-34.8%
Q3 24
-10.4%
-48.7%
Q2 24
-1.8%
-81.6%
Q1 24
1.7%
-129.4%
EPS (diluted)
CTRN
CTRN
TARS
TARS
Q4 25
$-0.86
$-0.17
Q3 25
$0.46
$-0.30
Q2 25
$0.11
$-0.48
Q1 25
$-1.70
$-0.64
Q4 24
$-0.86
$-0.57
Q3 24
$-2.21
$-0.61
Q2 24
$-0.42
$-0.88
Q1 24
$0.43
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTRN
CTRN
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$107.8M
$343.4M
Total Assets
$464.3M
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTRN
CTRN
TARS
TARS
Q4 25
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Q1 24
$298.5M
Total Debt
CTRN
CTRN
TARS
TARS
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Q1 24
$29.9M
Stockholders' Equity
CTRN
CTRN
TARS
TARS
Q4 25
$107.8M
$343.4M
Q3 25
$113.2M
$335.1M
Q2 25
$108.6M
$332.6M
Q1 25
$113.2M
$342.5M
Q4 24
$130.3M
$224.5M
Q3 24
$136.6M
$237.5M
Q2 24
$154.8M
$252.2M
Q1 24
$157.7M
$275.2M
Total Assets
CTRN
CTRN
TARS
TARS
Q4 25
$464.3M
$562.2M
Q3 25
$457.4M
$534.6M
Q2 25
$437.4M
$495.0M
Q1 25
$462.8M
$500.8M
Q4 24
$467.1M
$377.0M
Q3 24
$506.7M
$376.3M
Q2 24
$484.1M
$376.8M
Q1 24
$518.7M
$349.3M
Debt / Equity
CTRN
CTRN
TARS
TARS
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×
Q1 24
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTRN
CTRN
TARS
TARS
Operating Cash FlowLast quarter
$8.6M
$19.3M
Free Cash FlowOCF − Capex
$767.0K
$13.0M
FCF MarginFCF / Revenue
0.4%
8.6%
Capex IntensityCapex / Revenue
4.0%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$11.9M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTRN
CTRN
TARS
TARS
Q4 25
$8.6M
$19.3M
Q3 25
$3.9M
$18.3M
Q2 25
$-11.0M
$-29.4M
Q1 25
$28.5M
$-20.7M
Q4 24
$-18.4M
$-22.2M
Q3 24
$5.6M
$-8.7M
Q2 24
$-19.6M
$-14.4M
Q1 24
$23.3M
$-37.8M
Free Cash Flow
CTRN
CTRN
TARS
TARS
Q4 25
$767.0K
$13.0M
Q3 25
$-1.7M
$16.3M
Q2 25
$-13.1M
$-30.4M
Q1 25
$26.0M
$-21.2M
Q4 24
$-20.4M
$-22.3M
Q3 24
$1.7M
$-8.9M
Q2 24
$-21.2M
$-15.4M
Q1 24
$20.0M
$-38.0M
FCF Margin
CTRN
CTRN
TARS
TARS
Q4 25
0.4%
8.6%
Q3 25
-0.9%
13.8%
Q2 25
-6.5%
-29.6%
Q1 25
12.3%
-27.1%
Q4 24
-11.4%
-33.5%
Q3 24
0.9%
-18.6%
Q2 24
-11.4%
-37.8%
Q1 24
9.3%
-137.5%
Capex Intensity
CTRN
CTRN
TARS
TARS
Q4 25
4.0%
4.2%
Q3 25
2.9%
1.6%
Q2 25
1.0%
1.0%
Q1 25
1.2%
0.8%
Q4 24
1.1%
0.1%
Q3 24
2.2%
0.6%
Q2 24
0.9%
2.5%
Q1 24
1.5%
0.6%
Cash Conversion
CTRN
CTRN
TARS
TARS
Q4 25
Q3 25
1.01×
Q2 25
-12.59×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
6.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons